ME00569B - Poboljšana bakterijska vakcina mycoplasma hyopneumoniae - Google Patents
Poboljšana bakterijska vakcina mycoplasma hyopneumoniaeInfo
- Publication number
- ME00569B ME00569B MEP-2008-858A MEP85808A ME00569B ME 00569 B ME00569 B ME 00569B ME P85808 A MEP85808 A ME P85808A ME 00569 B ME00569 B ME 00569B
- Authority
- ME
- Montenegro
- Prior art keywords
- vaccine composition
- mixture
- mycoplasma hyopneumoniae
- group
- siv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 25
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 title claims abstract 17
- 241000700605 Viruses Species 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims abstract 44
- 229920002125 Sokalan® Polymers 0.000 claims abstract 10
- 230000036039 immunity Effects 0.000 claims abstract 10
- 239000002671 adjuvant Substances 0.000 claims abstract 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract 9
- 230000002503 metabolic effect Effects 0.000 claims abstract 9
- 229920001400 block copolymer Polymers 0.000 claims abstract 8
- 208000015181 infectious disease Diseases 0.000 claims abstract 8
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract 8
- -1 terpene hydrocarbons Chemical class 0.000 claims abstract 6
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 5
- 235000007586 terpenes Nutrition 0.000 claims abstract 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract 3
- 229940032094 squalane Drugs 0.000 claims abstract 3
- 229940031439 squalene Drugs 0.000 claims abstract 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract 3
- 241000725681 Swine influenza virus Species 0.000 claims 14
- 230000003053 immunization Effects 0.000 claims 13
- 241000202347 Porcine circovirus Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000003612 virological effect Effects 0.000 claims 9
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 241000606860 Pasteurella Species 0.000 claims 6
- 241000894006 Bacteria Species 0.000 claims 5
- 241000588779 Bordetella bronchiseptica Species 0.000 claims 5
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 230000001681 protective effect Effects 0.000 claims 4
- 244000052613 viral pathogen Species 0.000 claims 4
- 241000589902 Leptospira Species 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 241000204031 Mycoplasma Species 0.000 claims 2
- 241000282898 Sus scrofa Species 0.000 claims 2
- 229960001631 carbomer Drugs 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229920000178 Acrylic resin Polymers 0.000 claims 1
- 239000004925 Acrylic resin Substances 0.000 claims 1
- 241000186811 Erysipelothrix Species 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 241001138501 Salmonella enterica Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 229960001212 bacterial vaccine Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Pronalazak obezbeđuje poboljšanu kompoziciju bakterijske vakcine Mycoplasma hyopneumoniae, koja poželjno obezbeđuje imunitet od infekcija posle jednog davanja. Kompozicija se sastoji od inaktivirane bakterije Mycoplasma hyopneumoniae i smeše pomoćnih sredstava, koje u kombinaciji, obezbeđuju imunitet naspram Mycoplasma hyopneumoniae infekcije posle jednog davanja i izazivaju imuni odgovor specifičan na bakteriju Mycoplasma hyopneumoniae, uključujući imunitet posredovan ćelijama i lokalni (sekrecija IgA) imunitet. U poželjnom izvođenju, smeša pomoćnih sredstava se sastoji od polimera akrilne kiseline, najpoželjnije Carbopol-a i smeše metaboličnog ulja, kao što su jednom ili više nezasićeni terpenski ugljovodonici poželjno skvalen ili skvalan i polioksietilenpolioksipropilen blok kopolimera kao što je Pluronic®. Kompozicija vakcine može opciono uključivati konzervanse, poželjno timerosol i/iliEDTA. U još jednom izvođenju, pronalazak obezbeđuje poboljšanu kompoziciju vakcine naspram Mycopfasma hyopneumoniae, koja poželjno obezbeđuje imunitet od infekcije posle jednog davanja i sastoji se od inaktivirane Mycoplasma hyopneumoniae bakterije i pomoćnog sredstva ili smeše pomoćnih sredstava koje u kombinaciji obezbeđuju imunitet naspram Mycoplasma hyopneumoniae infekcije posle jednog davanja i izazivaju specifični imuni odgovor na Mycoplasma hyopneumoniae bakteriju uključuju imunitet posredovan ćelijama i lokalni (sekrecija IgA) imunitet u kombinaciji sa ostalim komponentama vakcine.
Claims (22)
1. Kompozicija vakcine za imunizaciju životinja protiv infekcije Mycoplasma hyopneumoniae i viralnog patogena, naznačena time, što uključujeimunizirajuću količinu bakterije Mycoplasma hyopneumoniae;imunizirajuću količinu bar jednog virusnog antigena i za branog iz grupe koju čine virus svinjskog gripa (SIV), v irus svinjskog r produktivnog i respiratmnog sindroma (PRRSV) svinjski cirkovirus (PCV);smešu pomoćnih sredstava koju čine polimer akr ilne kiseline i smeša metaboličnog ulja i polioksietilen-polioksipropilen blok kopolimera; ifarmaceutski prihvatljiv nosač, gde kompozicija vakcine posle jednog davanja t zazJva zaštitni imunitet od Mycoplasma hyopnewnoniae.
2. Kompozicija vakcine prema zahtevu l, naznačena time, što se smeša pomoćnih sredstava sastoj i od polimera akrilne k i se line i smeše metaboličnog ulja koje se sastoji od jednog ili v i še terpenskih ugljovodonika i polioksieti lena i polioksieti len-p olioksipropilen blok kopolimera u odnosu od oko 1:25 do 1:50 polimera akr iln e kiseline u odnosu na smeš u metabolično ulje/po lioksieti len-pol ioksipropilen blok kopolimera.
3. Kompozicija vakcine prema zahtevu l , naznačena time, što smeša pomoćnih sredstava čini oko 1-25% v/v kompozicije vakcine.
4. Kompozicija vakcine prema zahtevu 3, naznačena time, š to polimer akrilne kiseline je prisutan u koncentracUi od oko l% v/v i smeša terpenski ugljovodonici/polioksietilen-polioksipropi len b lok kopolimer je prisutna u krajnjoj koncentraciji od oko 5% do l 0% v/v.
5. Kompozicija vakcine prema zahtevu 3, naznačena time, što smeša pomoćnih sredstava se sastoji od oko 2%-15% v/v kompozicije vakcine.
6. Kompozicija vakcine prema zahtevu 5, naznačena time, što smeša pomoćnih sredstava se sastoji od oko 5%-12% v/v kompozicije vakcine.
7. Kompozicija vakcine prema zahtevu 1, naznačena time, što metabolično ulje je skvalan ili skvalen.
8. Kompozicija vakcine prema zahtevu 6 ili 7, naznačena time, što polimer akrilne kiseline je karbomer.
9. Kompozicija vakcine prema bilo kom zahtevu 1-8, naznačena time, što dalje uključuje bar jednu bakteriju izabranu iz grupe koju čine Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actionobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae i bakterija leptospire.
10. Kompozicija vakcine prema bilo kog od zahteva 1-8, naznačen time, što se dalje sastoji od bakterijskog ili virusnog antigena izabranog od jedne ili više od sledećih grupa, SIV; Haemonphilus parasuis; grupa se sastoji od PRRSV i PCV; grupa se sastoji od SIV i Erysipelothrix rhusiopathiae: grupa se sastoji od Pasteurella multiocida i Bord etella bronchiseptica .
11. Postupak zaštite životinja protiv bolesti uzrokovane sa Mycoplasma hyopneumoniae i bar još jednim virusnih antigenom, naznačen time, što uključuje stupanj davanja pomenutoj životinji kompozicije vakcine koja se sastoji od imunizirejuće kotičine bakterije Mycoplasma hyo.pneumoniae ; imunizirajuće količine bar jednog virusnog antigena izabranog iz grupe koju čine virus svinjskog gripa (SIV), virus svinjskog reproduktivnog i respiratornog sindroma (PRRSV) i svinjski cirkovirus (PCV); smeše pomoćnih sredstava koju čine polimer akrilne kiseline i smeša metaboličnog ulja i polioksietilen-polioksipropilen blok kopolimera; i farmaceutski prihvatljivog nosača, gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od infekcije Mycoplasma hyopneumoniae.
12. Postupak prema zahtevu 11, naznačen time, što imunizirajuća količina pomenute bakterije je oko lxl08 do 3xl0 11 MHDCE/ml.
13. Postupak prema zahtevu 12, naznačen time, što imunizirajuća količina pomenute bakterije je oko lx l 0 9 do 3x l 09 MHDCE/ml.
14. Postupak prema zahtevu 11, naznačen time, što način davanja u pomenutom stupnju davanja je intramuskularni, subkutanozni, intraperitonealni, aerosolom, oralno ili intranazalno.
15. Postupak prema zahtevu 11, naznačen time, što smeša pomoćnih sredstava se sastoji od polimera akrilne kiseline i smeše metaboličnog ulja koje čine jedan ili više terpenskih ugljovodonika i polioksietilen polioksipropilen blok kopolimera prisutan u krajnjoj koncentraciji od oko 1-25% v/v.
16. Postupak prema zahtevu 15, naznačen time, što polii·ner akrilne kiseline smeše pomoćnih sredstava je karbomer.
17. Postupak prema zahtevu 15, naznačen time, što metabolično ulje smeše pomoćnih sredstava je terpenski ugljovodonik izabran iz grupe koju čine skvalen i skvalan.
18. Postupak prema bilo kom od zahteva 11-17, naznačen t im e, što se dalje sastoji od zajedničkog davanja bar jedne dodatne bakteri je izabrane iz grupe koju čine Haemonphilus parasuis, Pasteurella n1.ultiocida, Streptococcum suis, Actionobacitlus pleuropneumoniae, Bordetetla bronchiseptica, Salmone/la choleraesuis, Erysipelothrix rhusiopathiae i bakterija leptospire.
19. Postupak prema zahtevima 11-17 za zaštitu ž i votinja naspram bolesti izazvnih sa Mycoplasma hyopneumoniae i bar jednog virusnog patogena i bar jednog dodatnog patogena, naznačen time, što dalje ukUučuje zajedničko davanje bar jednog dodatnog bakterijskog ili virusnog antigena izabranog od jednog ili više bakteriskih ili virusnih antigena izabranih iz jedne ili više sledećih grupa SIV; Haemonphilus parasuis; gmpe koja se sastoji od PRRSV i PCV; grup·e koja se sastoji od SIV i Erysipelothrix rhusiopathiae; grupe koja se sastoji od Pasteurellamultiocida i Bordetella bronchiseptica.
20. Kompozicija vakcine za imuniziranje životinja naspram infekcije Mycoplasma hyopneumoniae i virusnog patogena, naznačena time, što se sastoji od imunizirajuće količine bakterije Mycoplasma hyopneumoniae ; imunizirajuće količine bar jednog virusnog antigena izabranog iz grupe koju čine Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actionobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmone /la choleraesuis, Erysipelothrix rhusiopathiae, bakterija leptospira, virus svinjskog gripa (SIV), virus svinjskog reproduktivnog ·i respiratornog sindroma (PRRSV) i svinjski cirkovirus (PCV); bar jedno pomoćno sredstvo; i farmaceutski prihvatljivog nosača, gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od infekcije Mycoplasma hyopnewnoniae.
21. Kompozicija vakcine prem a zahtevu 20, naznačena time, što dalje sadrži bakterijski i virusni antigen i zabran iz jedne ili više sledećih grupa, SIV; Haemonphilus parasuis; grupe koja se sastoji od PRRSV i PCV; grupe koja se sastoj i od SIV i Erysipelothrix rhusiopath.iae; grupe koja se sastoji od Pasteurella multiocida i, Bor det ella bronchiseptica.
22. Kompozicija vakcine za imuniziranje ži vot in ja naspram infekcija f.1ycoplasma hyopneumoniae i v iru snih patogena, naznačena time, š to se sastoji od imunizirajuće količine bakterije f.1ycoplasma h.yopneum on.iae ; imunizirajuće količine bar jednog virusnog antigena i zabran og iz grupe koju čine virus svinjskog gripa (SIV), virus svinjskog reproduktivnog i respiratornog sindroma (PRRSV) svinjski cirkovirus (PCV); smešu pomoćnih sredstava koju čine polimer akri lne kise l ine i metaboličnog ulje i polioksietilen-polioksipropil en blok kopol i mer u obliku emulzije ulja u vodi; i gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od Mycoplasma hyopneumoniae .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/150,597 US7018638B2 (en) | 2000-12-19 | 2002-05-17 | Mycoplasma hyopneumoniae bacterin vaccine |
| PCT/US2003/015115 WO2004058142A2 (en) | 2002-05-17 | 2003-05-14 | Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ME00569B true ME00569B (me) | 2011-12-20 |
| ME00569A ME00569A (en) | 2011-12-20 |
Family
ID=32680190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-858/08A ME00569A (en) | 2002-05-17 | 2003-05-14 | Improved mycoplasma hyopneumoniae bacterin vaccine |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7018638B2 (me) |
| EP (2) | EP1506006B1 (me) |
| JP (2) | JP2006515304A (me) |
| KR (1) | KR101056622B1 (me) |
| CN (1) | CN1305524C (me) |
| AR (1) | AR039545A1 (me) |
| AU (1) | AU2003303129B2 (me) |
| BR (1) | BR0310082A (me) |
| CL (1) | CL2010000397A1 (me) |
| DK (1) | DK1870109T3 (me) |
| ES (2) | ES2569063T3 (me) |
| HR (1) | HRP20041068B1 (me) |
| ME (1) | ME00569A (me) |
| MX (1) | MXPA04011218A (me) |
| NZ (1) | NZ537014A (me) |
| RS (1) | RS54390B1 (me) |
| TW (1) | TWI320715B (me) |
| WO (1) | WO2004058142A2 (me) |
| ZA (1) | ZA200410153B (me) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE39494E1 (en) * | 1992-02-27 | 2007-02-27 | Intervet Inc. | Inactivated mycoplasma hyopneumoniae and uses therefor |
| DE69535059T2 (de) * | 1994-04-11 | 2007-01-18 | Wyeth Holdings Corp. | Borrelia burgdorferi bacterin |
| US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| JP3961222B2 (ja) * | 1999-03-08 | 2007-08-22 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Ｐｒｒｓｖワクチン |
| MXPA01010681A (es) * | 1999-04-22 | 2003-08-20 | Us Agriculture | Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado. |
| MY128159A (en) * | 2000-06-30 | 2007-01-31 | Wyeth Corp | Methods and composition for oral vaccination |
| MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| TWI238721B (en) * | 2003-06-20 | 2005-09-01 | Animal Technology Inst Taiwan | Swine enzootic vaccine, its producing method and usage |
| KR20070028547A (ko) * | 2004-06-18 | 2007-03-12 | 리전츠 오브 더 유니버스티 오브 미네소타 | 바이러스에 감염되고 백신접종된 생물의 동정 |
| US7632636B2 (en) * | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
| US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
| UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
| US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| US20060251827A1 (en) * | 2005-05-09 | 2006-11-09 | Applied Materials, Inc. | Tandem uv chamber for curing dielectric materials |
| SI1904631T1 (sl) | 2005-06-24 | 2012-09-28 | Univ Minnesota | Virusi PRRS, infekciozni kloni, njihovi mutanti in postopki uporabe |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| CA2628158C (en) * | 2005-11-04 | 2015-12-15 | Novartis Vaccines And Diagnostics S.R.L. | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| AU2006310336B2 (en) | 2005-11-04 | 2011-02-03 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| SG170792A1 (en) * | 2005-12-29 | 2011-05-30 | Boehringer Ingelheim Vetmed | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
| DK1968630T5 (en) * | 2005-12-29 | 2018-08-13 | Boehringer Ingelheim Vetmedica Inc | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS. |
| DK2007419T3 (da) * | 2006-04-10 | 2012-03-19 | Intervet Int Bv | Vaccine mod mycoplasma PRRSV |
| EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| WO2008076915A2 (en) | 2006-12-15 | 2008-06-26 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with pcv2 antigen |
| EP1941903A1 (en) * | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
| CL2008001806A1 (es) * | 2007-06-20 | 2008-09-05 | Wyeth Corp | Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion. |
| US20090017064A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| US7829274B2 (en) * | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
| AU2012261741B2 (en) * | 2007-11-06 | 2016-02-25 | Zoetis Services Llc | Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine |
| WO2009061798A1 (en) | 2007-11-06 | 2009-05-14 | Wyeth | Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine |
| CA2710558A1 (en) * | 2007-12-31 | 2009-07-16 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 virus like particle with foreign amino acid insertion |
| CN101980720A (zh) * | 2008-01-23 | 2011-02-23 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Pcv2猪肺炎支原体致免疫组合物及其制备方法 |
| US20110033495A1 (en) * | 2008-02-15 | 2011-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
| US8444989B1 (en) * | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
| CN101363865B (zh) * | 2008-05-26 | 2013-03-06 | 北京庄笛浩禾生物医学科技有限公司 | 一种猪蓝耳病毒胶体金检测试纸条、其制备方法及其应用 |
| JP5627581B2 (ja) * | 2008-06-25 | 2014-11-19 | ブラーシュ・バイオテック・エルエルシー | ソマトスタチン免疫原性増進のための組成物および方法 |
| US20100003278A1 (en) * | 2008-07-03 | 2010-01-07 | Boehringer Ingelheim Vetmedica, Inc. | Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof |
| BRPI0917887A2 (pt) * | 2008-08-25 | 2019-09-03 | Boehringer Ingelheim Vetmedica Inc | vacina contra síndrome reprodutiva e respiratória suína altamente patogênica (hp pprs) |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| US8546149B2 (en) | 2010-08-27 | 2013-10-01 | Intervet Inc. | Potency test for vaccine formulations |
| EP2609428B1 (en) * | 2010-08-27 | 2016-02-10 | Intervet International B.V. | Potency test for vaccine formulations |
| CN101954079B (zh) * | 2010-09-21 | 2012-11-28 | 江苏省农业科学院 | 猪支原体肺炎活疫苗的疫苗佐剂及其制备方法和应用 |
| DK2675475T3 (en) | 2011-02-17 | 2015-09-14 | Boehringer Ingelheim Vetmed | NEW EUROPEAN PRRSV TRIAL |
| MY183980A (en) | 2011-02-17 | 2021-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Commercial scale process for production of prrsv |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US9315781B2 (en) | 2011-07-29 | 2016-04-19 | Boehringer Ingelheim Vetmedica Gmbh | Infectious CDNA clone of european PRRS virus and uses thereof |
| US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
| CN103157100B (zh) * | 2011-12-08 | 2014-09-24 | 普莱柯生物工程股份有限公司 | 副猪嗜血杆菌病、猪链球菌病二联灭活疫苗及其制备方法 |
| US9474692B2 (en) * | 2012-01-13 | 2016-10-25 | Boehringer Ingelheim Vetmedica Gmbh | Kit for the preparation of a vaccinating agent |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| US9878027B2 (en) * | 2012-12-28 | 2018-01-30 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition comprising mycoplasma antigens |
| EP2938747B1 (en) | 2012-12-28 | 2019-05-01 | Boehringer Ingelheim Vetmedica GmbH | Method of making a mycoplasma vaccine |
| CN103908665B (zh) * | 2013-01-05 | 2016-05-25 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| CN103071151B (zh) * | 2013-01-17 | 2014-07-23 | 江苏省农业科学院 | 猪支原体肺炎疫苗专用稀释剂及其制备方法 |
| CN103961695B (zh) * | 2013-02-06 | 2016-09-07 | 普莱柯生物工程股份有限公司 | 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用 |
| CN105073130A (zh) | 2013-03-15 | 2015-11-18 | 勃林格殷格翰动物保健公司 | 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法 |
| CN104096222B (zh) * | 2013-04-08 | 2016-09-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| PL2994162T3 (pl) | 2013-05-08 | 2021-10-18 | Pharmgate Biologics Inc. | Szczepionka przeciwko pcv2 i mykoplazmie |
| MX373669B (es) | 2013-09-25 | 2020-04-02 | Zoetis Services Llc | Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. |
| CN105658660A (zh) | 2013-10-02 | 2016-06-08 | 勃林格殷格翰动物保健公司 | Pcv2 orf2蛋白变体和由其组成的病毒样颗粒 |
| CN104248759B (zh) * | 2013-11-19 | 2017-05-10 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| CN104857508B (zh) * | 2014-02-21 | 2018-03-16 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| US10064930B2 (en) * | 2015-01-16 | 2018-09-04 | Boehringer-Ingelheim Vermedica, Inc. | Immunogenic compositions and methods for pigeon fever |
| EP4588579A3 (en) * | 2015-11-13 | 2025-10-22 | Targan Inc. | System and method of determining the health & gender of a chick |
| CN111346224B (zh) | 2018-12-24 | 2023-12-08 | 洛阳赛威生物科技有限公司 | 一种免疫佐剂组合物及其制备方法和应用 |
| CN112618710B (zh) * | 2019-09-24 | 2023-09-29 | 华南理工大学 | 一种植物糖原猪口服接种疫苗纳米佐剂及其制备方法与应用 |
| TW202510910A (zh) * | 2023-06-28 | 2025-03-16 | 國立感染症研究所長代表之日本國 | 疫苗佐劑組成物及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3790665A (en) * | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| JPH0832637B2 (ja) * | 1985-02-14 | 1996-03-29 | アクゾ・エヌ・ヴエー | 合成免疫原 |
| ZA881694B (en) | 1987-03-17 | 1988-09-06 | Akzo N.V. | Adjuvant mixture |
| EP0315153B1 (en) | 1987-11-03 | 1994-05-11 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
| ZA906806B (en) * | 1989-08-31 | 1991-06-26 | Ici Australia Operations | Plants |
| ES2112274T5 (es) * | 1990-05-29 | 2006-03-01 | Wyeth Holdings Corporation | Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma. |
| US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| NZ285324A (en) | 1994-05-10 | 1998-08-26 | American Home Prod | Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier |
| US6517843B1 (en) * | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| US6632439B2 (en) * | 1999-09-29 | 2003-10-14 | Novartis Animal Health, Inc. | Fusobacterium necrophorum vaccine and method for making such vaccine |
| US6585981B1 (en) * | 2000-07-27 | 2003-07-01 | Regents Of The University Of Minnesota | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae |
| MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
-
2002
- 2002-05-17 US US10/150,597 patent/US7018638B2/en not_active Expired - Lifetime
-
2003
- 2003-05-13 TW TW092112918A patent/TWI320715B/zh not_active IP Right Cessation
- 2003-05-14 CN CNB038110989A patent/CN1305524C/zh not_active Expired - Lifetime
- 2003-05-14 HR HRP20041068AA patent/HRP20041068B1/hr not_active IP Right Cessation
- 2003-05-14 EP EP03813041.5A patent/EP1506006B1/en not_active Expired - Lifetime
- 2003-05-14 NZ NZ537014A patent/NZ537014A/en not_active IP Right Cessation
- 2003-05-14 RS YU99704A patent/RS54390B1/sr unknown
- 2003-05-14 WO PCT/US2003/015115 patent/WO2004058142A2/en not_active Ceased
- 2003-05-14 ME MEP-858/08A patent/ME00569A/xx unknown
- 2003-05-14 JP JP2004563182A patent/JP2006515304A/ja not_active Withdrawn
- 2003-05-14 MX MXPA04011218A patent/MXPA04011218A/es active IP Right Grant
- 2003-05-14 BR BRPI0310082-0A patent/BR0310082A/pt not_active Application Discontinuation
- 2003-05-14 AU AU2003303129A patent/AU2003303129B2/en not_active Expired
- 2003-05-14 ES ES07019279.4T patent/ES2569063T3/es not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018602A patent/KR101056622B1/ko not_active Expired - Lifetime
- 2003-05-14 EP EP07019279.4A patent/EP1870109B1/en not_active Expired - Lifetime
- 2003-05-14 ES ES03813041T patent/ES2431988T3/es not_active Expired - Lifetime
- 2003-05-14 DK DK07019279.4T patent/DK1870109T3/en active
- 2003-05-16 AR ARP030101717A patent/AR039545A1/es not_active Application Discontinuation
-
2004
- 2004-12-15 ZA ZA2004/10153A patent/ZA200410153B/en unknown
-
2005
- 2005-12-27 US US11/318,983 patent/US7169394B2/en not_active Expired - Lifetime
-
2007
- 2007-01-11 US US11/652,306 patent/US7622124B2/en not_active Expired - Lifetime
-
2009
- 2009-11-16 US US12/618,842 patent/US7959927B2/en not_active Expired - Fee Related
-
2010
- 2010-04-21 CL CL2010000397A patent/CL2010000397A1/es unknown
-
2013
- 2013-04-30 JP JP2013095322A patent/JP5700861B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00569B (me) | Poboljšana bakterijska vakcina mycoplasma hyopneumoniae | |
| CN1315534C (zh) | 用于牛呼吸系统和生殖系统的疫苗 | |
| EP2217271B1 (en) | Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine | |
| ME00570A (en) | Improved mycoplasma hyopneumoniae bacterin vaccine | |
| Marchioro et al. | Local and systemic immune responses in pigs intramuscularly injected with an inactivated Mycoplasma hyopneumoniae vaccine | |
| CA2836805A1 (en) | Bovine vaccines and methods | |
| CA2646574C (en) | Vaccine against mycoplasma and prrsv | |
| EP3723795A1 (en) | A vaccine for protection against streptococcus suis | |
| US20050089533A1 (en) | Canine vaccines against Bordetella bronchiseptica | |
| WO2020094762A1 (en) | A vaccine for protection against streptococcus suis | |
| US5695769A (en) | Pasteurella multocida toxoid vaccines | |
| Brogden et al. | Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs | |
| de Bagüés et al. | Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis | |
| JP4105220B2 (ja) | 精巣ｂｖｄｖ感染に対するワクチン接種方法 | |
| EP0894500A1 (en) | Streptococcus equi vaccine | |
| WO2022072431A1 (en) | Novel pasteurella multocida strains and vaccines having hyac and nanp deletions | |
| US12071636B2 (en) | Pasteurella multocida strains and vaccines having hyaC and nanP deletions | |
| AU669681B2 (en) | Pasteurella multocida toxoid vaccines | |
| JPH05201877A (ja) | アジュバント組成物 | |
| WO2025064844A1 (en) | Porcine sapovirus isolates and immunogenic compositions therefrom | |
| Eichmeyer et al. | Efficacy of Ingelvac® PRRS MLV when rehydrated with a combination of Ingelvac MycoFLEX® and Ingelvac CircoFLEX® | |
| JP2024527138A (ja) | 様々な血清型のストレプトコッカス・スイスに対して保護するためのワクチン | |
| Fangman et al. | Serologic response of weaned pigs vaccinated with 3FLEX™ is similar to pigs vaccinated with Ingelvac® CircoFLEX-MycoFLEX™ and Ingelvac® PRRS MLV in separate injections |